Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Glenmark Life Sciences IPO is a book build issue of ₹1,513.60 crores. The issue is a combination of fresh issue of 1.47 crore shares aggregating to ₹1,060.00 crores and offer for sale of 0.63 crore shares aggregating to ₹453.60 crores.
Glenmark Life Sciences IPO bidding started from Jul 27, 2021 and ended on Jul 29, 2021. The allotment for Glenmark Life Sciences IPO was finalized on Aug 3, 2021. The shares got listed on BSE, NSE on Aug 6, 2021.
Glenmark Life Sciences IPO price band is set at ₹720.00 per share . The lot size for an application is 20. The minimum amount of investment required by an retail is ₹13,900 (20 shares). The lot size investment for sNII is 14 lots (280 shares), amounting to ₹2,01,600, and for bNII, it is 70 lots (1,400 shares), amounting to ₹10,08,000.
BOFA Securities India Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Glenmark Life Sciences IPO RHP for detailed Information.
| IPO Date | July 27, 2021 to July 29, 2021 |
| Listing Date | August 6, 2021 |
| Face Value | ₹2 per share |
| Issue Price Band | ₹695 to ₹720 per share |
| Issue Price Final | ₹720 per share |
| Lot Size | 20 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 2,10,22,222 shares (aggregating up to ₹1,513.60 Cr) |
| Fresh Issue | 1,47,22,222 shares (aggregating up to ₹1,060.00 Cr) |
| Offer for Sale | 63,00,000 shares of ₹2 (aggregating up to ₹453.60 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 10,78,04,950 shares |
| Share Holding Post Issue | 12,25,27,172 shares |
Glenmark Life Sciences IPO offers total 2,10,22,222 shares. Out of which 1,05,11,110 (50.00%) allocated to QIB, 42,04,450 (20.00%) allocated to QIB, 31,53,334 (15.00%) allocated to NII, 73,57,778 (35.00%) allocated to RII and 63,06,660 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 1,05,11,110 (50.00%) | NA |
| − Anchor Investor Shares Offered | 63,06,660 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 42,04,450 (20.00%) | NA |
| NII (HNI) Shares Offered | 31,53,334 (15.00%) | NA |
| Retail Shares Offered | 73,57,778 (35.00%) | 3,67,888 |
| Total Shares Offered | 2,10,22,222 (100.00%) |
Glenmark Life Sciences IPO opens on July 27, 2021, and closes on July 29, 2021.
| IPO Open Date | Tue, Jul 27, 2021 |
| IPO Close Date | Thu, Jul 29, 2021 |
| Tentative Allotment | Tue, Aug 3, 2021 |
| Initiation of Refunds | Wed, Aug 4, 2021 |
| Credit of Shares to Demat | Thu, Aug 5, 2021 |
| Tentative Listing Date | Fri, Aug 6, 2021 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Jul 29, 2021 |
Investors can bid for a minimum of 20 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,400 |
| Retail (Max) | 13 | 260 | ₹1,87,200 |
| S-HNI (Min) | 14 | 280 | ₹2,01,600 |
| S-HNI (Max) | 69 | 1,380 | ₹9,93,600 |
| B-HNI (Min) | 70 | 1,400 | ₹10,08,000 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive strengths
| Particulars | For the year/period ended (₹ in million) | ||||
|---|---|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |||
| Total Assets | 19,970.75 | 17,256.04 | 14,753.95 | ||
| Total Revenue | 18,859.76 | 15,493.03 | 8,868.65 | ||
| Profit After Tax | 3,515.81 | 3,130.98 | 1,955.92 | ||
The Company Glenmark Life Sciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018 | 800.00 |
| 2 | Funding the capital expenditure requirements | 152.76 |
| 3 | General corporate purposes | 57.68 |
[Dilip Davda] Though this is a second public issue from Glenmark group after nearly two decades, it is encasing on the fancy of pharma segment amidst pandemic and hence the issue is fully priced discounting all near term positives. Considering the group's credentials and ongoing grey market activities the IPO may evoke a good response. Cash surplus investors may consider investing in this offer with a long term perspective. Read detail review...
| Listing Date | August 6, 2021 |
| BSE Script Code | 543322 |
| NSE Symbol | ALIVUS |
| ISIN | INE03Q201024 |
| Final Issue Price | ₹720 per share |
| BSE Listing Group | B |
Glenmark Life Sciences Ltd.
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,
Mohol, Maharashtra
Phone: +91 2189 234456/ +91 2189
Email: complianceofficer@glenmarklifesciences.com
Website: http://www.glenmarklifesciences.com/
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: glenmark.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Lead Manager Reports
Glenmark Life Sciences IPO is a main-board IPO of 2,10,22,222 equity shares of the face value of ₹2 aggregating up to ₹1,513.60 Crores. The issue is priced at ₹720 per share. The minimum order quantity is 20.
The IPO opens on July 27, 2021, and closes on July 29, 2021.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Glenmark Life Sciences IPO using UPI as a payment gateway. Zerodha customers can apply in Glenmark Life Sciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Glenmark Life Sciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Glenmark Life Sciences IPO opens on July 27, 2021 and closes on July 29, 2021.
Glenmark Life Sciences IPO lot size is 20, and the minimum amount required for application is ₹14,400.
You can apply in Glenmark Life Sciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Glenmark Life Sciences IPO will be done on Tuesday, August 3, 2021, and the allotted shares will be credited to your demat account by Thursday, August 5, 2021. Check the Glenmark Life Sciences IPO allotment status.
The Glenmark Life Sciences IPO listing date is on Friday, August 6, 2021.
Useful Articles
RHP